What an approval actually covers

Product, indication, jurisdiction

An FDA approval names a product, a manufacturer’s quality system, a dose form, and a use. Forzinity is elamipretide, approved on 19 September 2025, accelerated, for muscle strength in Barth syndrome when the patient weighs at least 30 kilograms. It is not an approval of “SS-31” as sold by a research catalog, and it is not an anti-aging approval.

The same split applies to semaglutide, tirzepatide, tesamorelin, and bremelanotide. Ozempic, Wegovy, Mounjaro, Zepbound, Egrifta, and Vyleesi are licensed products with labels. A lyophilized vial is a different object even when the peptide sequence matches.

Accelerated is not the end of the question

Accelerated approval can rest on a measure that is reasonably likely to predict a real benefit, rather than on the benefit itself. For Forzinity, that measure was knee-extension strength. The agency required a later randomized trial to confirm that the strength change matters to patients. Until that confirmation, the limitation is part of the approval, not a footnote.

A successful trial is also not an approval. Retatrutide’s TRIUMPH-1 paper is peer-reviewed phase 3 evidence about the sponsor’s formulation. No approved retatrutide product was identified for this index.

Outside one country

Thymalfasin has been licensed outside the United States for specific uses. Semax and Selank have registrations in Russia. Those facts do not make a US research powder into the licensed product, and the exact current label is country-specific. This site does not copy a foreign indication list it has not re-read.